Antibody Specificity, Affinity and Kinetics in a Single Experiment
The emerging non-traditional antibody formats are often more efficacious, reaching new therapeutic targets including crossing the blood-brain barrier. Formats that retain the basic structure of IgGs may inherit their pharmacokinetic properties but lack the Fc-part of the antibody and can have shorter half-lives.
The smaller antibody formats such as single-chain fragment variables, nanobodies or other scaffolds that can reach hidden targets or act as intrabodies to target intracellular antigens must strike a balance between efficacy and half-life.
Watch this webinar to learn more about:
- Applications for screening and characterizing antibody and antibody fragments
- A label-free technology which uses surface plasmon resonance (a biophysical technology) for characterizing antibodies